Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Pharma Inc.

www.astellas.com

Latest From Astellas Pharma Inc.

Innovation Ecosystem Needs More Support, BioJapan Hears

Head of industry group in Japan makes personal plea at major biotech meeting for improvements to Japan’s innovation ecosystem, as government representatives say steps are already being taken to improve collaborative research and foster bioventures.

Japan Innovation

Deal Watch: Astellas/Cytokinetics Extend Partnership, Make Progress On SMA Candidate

The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.

Deals Business Strategies

Master Key Project Aims To Unlock Japan Rare Cancer Drug Development

Japan's National Cancer Center is progressing a collaborative project with industry to encourage the development of targeted therapies for rare cancers, as part of wider efforts to support early access to personalized oncology drugs.

Japan Cancer

ECHELON-2 Ushers In Another New Adcetris Indication For Seattle Genetics

The combination of Adcetris with chemotherapy improved progression-free and overall survival in peripheral T-cell lymphoma. Filing is expected soon, and approval will help the product reach blockbuster status.

Clinical Trials Cancer
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register